Skip to main content

Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study

Hepatology International volume 6, pages 763–769 (2012)Cite this article

Abstract

Purpose

Hepatocellular carcinoma (HCC) is the most common cancer in Mongolia. We aimed to investigate the clinical features, therapeutic modalities, overall survival and prognostic factors for Mongolian patients with HCC.

Method

One hundred ninety-five patients with HCC were consecutively enroled in our study.

Results

The mean age was 61.7 years. The most common etiology for HCC was HCV infection (n = 89, 45.6%), followed by HBV infection (n = 67, 34.4%). The mean tumor diameter was 6.0 ± 2.6 cm. Only 29 (14.9%) patients had a single lesion, while 39 (20.2%) had >3 lesions. Extrahepatic metastasis to lung (n = 23), bone (n = 10) and lymph node (n = 3) were detected in 36 (18.5%) patients. Most patients had advanced HCC—88 (45.1%) in stage III and 57 (29.2%) in stage IV. Surgical resection was performed in 27 (13.8%) patients, RFA in 23 (11.8%) and TACE in 107 (54.9%). When all the patients were categorized as ‘treated’ (n = 156) and ‘not treated’ (n = 39), the 3-year survival was significantly lower in the ‘not treated’ group than in the ‘treated’ group (11 vs. 0%, P < 0.001). Tumor diameter (<3 cm vs. ≥3 cm), extrahepatic metastasis, TNM stage (I/II vs. III/IV) and treatment (or supportive care) were selected as independent predictors for survival.

Conclusions

High proportion of patients with HCC in Mongolia is diagnosed at an advanced stage and survival of these patients is lower compared to other countries. A surveillance system and referral policy for high-risk groups should be urgently established and implemented in Mongolia.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. El-Serag HB. Hepatocellular carcinoma. An epidemiologic view. J Clin Gastroenterol 2002;35(suppl. 2):S72–S78

    PubMed  Article  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. 2002. Cancer J Clin 2005;55:74–108

    Article  Google Scholar 

  3. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750

    PubMed  Article  CAS  Google Scholar 

  4. McGlynn KA, Tsao L, Hsing AW, et al. International trends and patterns of primary liver cancer. Int J Cancer 2001;94:290–296

    PubMed  Article  CAS  Google Scholar 

  5. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002;62(suppl 1):8–17

    PubMed  Article  Google Scholar 

  6. Han K-H, Ahn SH. How to predict hepatocellular carcinoma development in patients with chronic B viral liver disease. Intervirology 2005;48:23–28

    PubMed  Article  Google Scholar 

  7. Ahn SH, Yuen L, Han KH, et al. Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol 2010;82:1126–1134

    PubMed  Article  CAS  Google Scholar 

  8. Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (Fibroscan). Hepatology 2011;53:885–894

    PubMed  Article  CAS  Google Scholar 

  9. Nymadawa P. Hepatitis B vaccination: worldwide and in Mongolia, 2004. In The 10th National Conference “Current Topics of Virology” (Abstracts), p. 115–116

  10. Baatarkhuu O, Kim DY, Ahn SH, et al. Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study. Liver Int 2008;28:1389–1395

    PubMed  Article  Google Scholar 

  11. Health Indicators. National Health Development Center, Mongolia. ed.; 2004.

  12. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030–3044

    PubMed  Article  CAS  Google Scholar 

  13. Kim SU, Han KH, Nam CM, et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol 2008;23:1722–1727

    PubMed  Article  Google Scholar 

  14. Kim Do Y, Kim SU, Ahn SH, et al. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci 2009;54:1758–1763

    PubMed  Article  Google Scholar 

  15. Lee JM, Park JY, Kim Do Y, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010;15:235–241

    PubMed  Article  CAS  Google Scholar 

  16. Bruix J, Sherman M, Llovet JM, et al. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona 2000 EASL conference. European Association for the Study of Liver. J Hepatol 2001;35:421–430

    PubMed  Article  CAS  Google Scholar 

  17. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer (English ed.) Kanehara & Co, Ltd: Tokyo; 2003

  18. Borzio M, Colleredo G, Pioltelli P, et al. Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis 2007;39:1011–1017

    PubMed  Article  CAS  Google Scholar 

  19. Markovic S, Gadzijev E, Stabuc B, et al. Treatment options in western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol 1998;29:650–659

    PubMed  Article  CAS  Google Scholar 

  20. Stroffolini T, Andreone P, Andriulli A, et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998;29:944–952

    PubMed  Article  CAS  Google Scholar 

  21. Amarsanaa J, Baatarkhuu O, Chinburen J. Current situation of HCC in Mongolia. Mong J Oncol 2010;4:15–19

    Google Scholar 

  22. Kondo Y, Mizokami M, Nakano T, et al. Prevalence and molecular epidemiology of GB virus C/hepatitis G virus infection in Mongolia. J Med Virol 1997;52:143–148

    PubMed  Article  CAS  Google Scholar 

  23. Takahashi M, Nishizawa T, Gotanda Y, et al. High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia. Clin Diagn Lab Immunol 2004;11:392–398

    PubMed  Google Scholar 

  24. Tsatsralt-Od B, Takahashi M, Nishizawa T, et al. High prevalence of hepatitis B, C, and delta virus infections among blood donors in Mongolia. Arch Virol 2005;150:2513–2528

    PubMed  Article  CAS  Google Scholar 

  25. Oyunsuren Ts, Sanduijav R, Davaadorj D, et al. Hepatocellular carcinoma and its early detection by AFP testing in Mongolia. Asian Pac J Cancer Prev 2006;7:460–462

    PubMed  Google Scholar 

  26. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007;96:1127–1134

    PubMed  Article  CAS  Google Scholar 

  27. WHO and National Cancer Center of Mongolian Report. Sub-programme on cancer prevention and control Ulaanbaatar 2009

  28. Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis 2007;11:817–837

    PubMed  Article  Google Scholar 

  29. Tremosini S, Reig M, de Lope CR, et al. Treatment of early hepatocellular carcinoma: towards personalized therapy. Dig Liver Dis 2010;42(Suppl 3):S242–S248

    PubMed  Article  Google Scholar 

  30. Lencioni R. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology 2010;78(Suppl 1):107–112

    PubMed  Article  Google Scholar 

  31. El-Serag HB, Kramer JR, Chen GJ, et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut 2011;60:992–997

    PubMed  Article  CAS  Google Scholar 

  32. Ahnmad K. Pakistan: a cirrhotic state? Lancet 2004;364:1843–1844

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported partly by the Grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (no. A102065) and partly by funds from Yonsei Liver Blood Bank (YLBB).

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, 120-752, Seoul, South Korea

    Oidov Baatarkhuu, Do Young Kim, Seung Up Kim, Kwang-Hyub Han & Sang Hoon Ahn

  2. Department of Infectious Diseases, Health Sciences University, Ulaanbaatar, Mongolia

    Oidov Baatarkhuu, Naran Khorolsuren & Ravjir Oyungerel

  3. Mongolian Academy of Medical Science, Ulaanbaatar, Mongolia

    Pagbajabyn Nymadawa & Kwang-Hyub Han

  4. Department of Radiology, Health Sciences University, Ulaanbaatar, Mongolia

    Dagvasumberel Gonchigsuren

  5. Department of Surgery, National Cancer Center, Ulaanbaatar, Mongolia

    Ravjir Sanduijav

  6. Department of Radiology, General Hospital #3, Ulaanbaatar, Mongolia

    Zundui Lkhagvasuren

  7. Mongolian Association for the Study of Liver Diseases, Ulaanbaatar, Mongolia

    Oidov Baatarkhuu & Jazag Amarsanaa

  8. Liver Cirrhosis Clinical Research Center, Seoul, South Korea

    Oidov Baatarkhuu, Do Young Kim, Seung Up Kim, Kwang-Hyub Han & Sang Hoon Ahn

  9. Brain Korea 21 Project for Medical Sciences, Seoul, South Korea

    Kwang-Hyub Han & Sang Hoon Ahn

Authors
  1. Oidov Baatarkhuu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Do Young Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pagbajabyn Nymadawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seung Up Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kwang-Hyub Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jazag Amarsanaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dagvasumberel Gonchigsuren
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ravjir Sanduijav
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zundui Lkhagvasuren
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naran Khorolsuren
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ravjir Oyungerel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sang Hoon Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sang Hoon Ahn.

Additional information

O. Baatarkhuu and D. Y. Kim equally contributed to this work.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Baatarkhuu, O., Kim, D.Y., Nymadawa, P. et al. Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study. Hepatol Int 6, 763–769 (2012). https://doi.org/10.1007/s12072-011-9325-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-011-9325-4

Keywords

  • Hepatocellular carcinoma
  • Survival
  • Mongolia